PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE TEVA SUMMER CE SYMPOSIUM IN FORT WORTH, TEXAS
MINNEAPOLIS, MINNESOTA, USA, July 29, 2024 /EINPresswire.com/ -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced today it will be exhibiting at the Texas Equine Veterinary Association (“TEVA”) 2024 Summer CE Symposium to be held August 1st to August 3rd 2024 at the Worthington Renaissance Hotel in Fort Worth, Texas.
PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology. Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to absorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
“The TEVA Symposium provides us an excellent event to demonstrate to leading equine veterinarians our innovative medical device for the management of osteoarthritis, Spryng, with OsteoCushion Technology” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “We welcome the opportunity to support TEVA and participate in this symposium to explain the advantages of Spryng including the beneficial results we have witnessed when administered to horses throughout the United States.”
For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit https://petvivo.com/
Conference Details:
Texas Equine Veterinary Association Exhibit Details:
Booth/Table #: 67
Dates:
Thursday, August 1, 2024 10:00am – 7:00pm
Friday, August 2, 2024 10:00am – 3:30pm
Location: The Worthington Renaissance Fort Worth Hotel, Fort Worth, Texas
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQB: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intraarticular injectable medical device for the management of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale.
For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact info1@petvivo.com or visit https://petvivo.com/.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
John Lai
Petvivo Holdings, Inc.
+1 (952) 405-6216